Information Provided By: 
Fly News Breaks for July 12, 2017
MDCO
Jul 12, 2017 | 07:30 EDT
Oppenheimer analyst Jay Olson says The Medicines Co. shares could see a 14% increment in value if the August PDUFA for carbavance results in FDA approval. The analyst assumes an 88% chance of this upside scenario based on published data for anti-infectives. The analyst also expects The Medicines Co. to leverage a potential carbavance approval to raise cash for funding development of inclisiran, potentially via a non-dilutive deal. Olson reiterates a Perform rating on the shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
